Connect← Return to ARSI (Lutamids) 3rd generation
Discussion
ARSI (Lutamids) 3rd generation
Prostate Cancer | Last Active: Sep 22 8:50am | Replies (6)Comment receiving replies
No!
I heard from someone here that Erleada works only for an average of 44 months. The new 3-third generation (ARSI) is about three times more effective and have 10-15 years protects against BCR
Replies to "@brianjarvis No! I heard from someone here that Erleada works only for an average of 44..."
@denis76
Hi Denis, do you mean the new class of androgen receptor degraders (and PROTACs) like the one in this article -> https://pubs.acs.org/jmcmar/article-abstract/69/14/16346/5206722/Discovery-of-Potential-First-in-Class-Dual-Ligand
Connect
@denis76 Each of the ARPIs was developed to improve on some shortcoming of the previous one(s); but each has its own strengths and weaknesses.
The 2nd generation androgen receptor pathway inhibitor (ARPI) therapies have all been available here in the U.S. for some time:
> Zytiga (abiraterone): 4/28/2011
> Xtandi (enzalutimide): 8/21/2012
> Erleada (apalutimide): 2/14/2018
> Nubeqa (darolutamide): 7/30/2019
(Over the past few years, I’ve attended webinars about them. See attached graphics for more information about them.)